Computed Tomography Screening for Lung Cancer without a Smoking Cessation Program—Not a Cost-Effective Idea
Identifying Inhibitors of Epithelial-Mesenchymal Transition by Connectivity Map–Based Systems Approach
Combined Effect of Genetic Polymorphisms in P53, P73, and MDM2 on Non-small Cell Lung Cancer Survival
BV6, an IAP Antagonist, Activates Apoptosis and Enhances Radiosensitization of Non-small Cell Lung Carcinoma In Vitro
Prolonged Survival in Patients with Lung Cancer with Diabetes Mellitus
Epithelial-Specific Methylation Marker
C609T Polymorphism of NAD(P)H Quinone Oxidoreductase 1 As a Predictive Biomarker for Response to Amrubicin
Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer
Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States
Subtyping of Non-small Cell Lung Carcinoma
Implications of Delayed Initiation of Radiotherapy
Prognostic Impact of Number of Resected and Involved Lymph Nodes at Complete Resection on Survival in Non-small Cell Lung Cancer
Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)
Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy
Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma
Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations
Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer
Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer
Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma
Complete Pathologic Response in Lung Tumors in Two Patients with Metastatic Non-small Cell Lung Cancer Treated with Erlotinib
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America
Osteonecrosis of the Humeral Head in a Patient with Non-small Cell Lung Cancer Receiving Bevacizumab
Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib
Peripheral Skin Edema as Unusual Toxicity in Three Patients with Advanced Non-small Cell Lung Cancer Treated with Pemetrexed Alone or in Combination with Cisplatin
Quantitative Computed Tomography Analysis of Emphysema and Lung Cancer Risk
Quantitative Computed Tomography Analysis of Emphysema and Lung Cancer Risk